Imugene Limited (ASX: IMU), which is in the business of clinical stage immuno-oncology, IS building up a range of new and novel immunotherapies that try to activate the immune system of malignancy patients to treat tumors. The company’s extraordinary stage innovation tries to tackle the body’s immune system to create antibodies against cancers, possibly accomplishing a comparable or more prominent impact than artificially made monoclonal antibody treatments. The product pipeline incorporates various immunotherapy B-cell vaccine aimed at treating an assortment of cancers in the mix with the standard care drugs and developing immunotherapies.
On 26 February 2019, the company reported that the Phase 1 clinical preliminary information for its B cell peptide cancer vaccine B-Vaxx has been published in the renowned American Association for Cancer Research journal Clinical Cancer Research.
The title of the article is “Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors,” and is fundamentally authored by Imugene’s SAB members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.
This first-in-human Phase 1 study assessed about the safety profile, ideal immunologic/biologic dose (OID/OBD) and immunogenicity of the blend of two peptides B-cell epitope vaccines designed to represent the trastuzumab and pertuzumab HER-2 binding sites. While the billion-dollar blockbusters marketed by Roche/Genentech Herceptin and Perjeta have been affirmed for clinical use, patients regularly develop resistance from these treatments.
Professor Pravin Kaumaya remarked, “We have propelled another example in immunotherapy that centres around humoral reactions dependent on conformational B-cell epitope antibodies”. He also stated that the vaccine is safe, displays hostile to tumor action and shows preliminary signs that peptide vaccination may avoid remedial obstruction and offers a promising option in contrast to monoclonal antibody treatments.
On 30 January 2019, the company updated about its quarterly result and overall business. It updated about HER-Vaxx Phase 1b gastric cancer study being completed and it is driving towards the phase 2 study of HER-Vaxx cancer vaccine in early 2019.
The company reported a nominal increase in its cash and cash equivalents from A$23.83 million in quarter ended 30th September 2018 to A$24.05 million in quarter ended 31st December 2019. It also made A$150k net cash from financing activities in quarter ended 31st December 2019 which contributed to the overall net cash from financing activities of 2nd half of 2018 to A$18.82 million. The company reported A$46K outflow from investing activities and A$57K inflow from operating activities.
The stock increased to A$0.18 in the opening session (26 February), but till the closing of trading it lost all the gains during the day and closed flat at A$0.016. The stock has offered a negative YTD return of 11.1 % as on 25 February 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.